Navigation Links
Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease
Date:9/2/2009

OMAHA, Neb. and HOUSTON, Sept. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

The analytic technology forms the basis for the NuroPro(R)PD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

The article describes the use of analytically validated quantitative 2D gel electrophoresis to identify protein biomarkers for diagnosing PD using serum from routinely collected blood samples. 57 protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls. A multi-variate statistical method, stepwise linear discriminant analysis, selected a combination of 21 of the biomarkers as optimal to distinguish PD patients from controls. When applied to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classif
'/>"/>

SOURCE Transgenomic, Inc.; Power3 Medical Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2009 Results
2. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
4. Transgenomic, Inc. Announces Appointment of New Board Members
5. Transgenomic, Inc. Reports First Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
8. Webcast Alert: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
9. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
10. Polycystic Kidney Disease Assay at Cornell University Uses Transgenomics Surveyor Nuclease & WAVE Technology
11. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
(Date:9/15/2014)... 2014 Zymo Research Corp., has announced the ... safe ambient temperature storage and transport of infectious ... of agents in such samples is completely inactivated ... the viral nucleic acids for subsequent analyses.  With ... in West Africa and ...
(Date:9/15/2014)... 2014 Applied Silicone Corporation, a ... the medical device and critical healthcare market, introduces ... implantable medical device market. The Dual Matrix ... a silicone gel with improved fracture resistance, cohesive ... consists of two crosslinked networks working in conjunction ...
(Date:9/15/2014)... 2014  The second annual International Plasma Awareness ... joint initiative of the Plasma Protein Therapeutics Association ... is designed to: , Raise global awareness ... of plasma donors in saving and improving lives ... rare diseases Member companies are planning ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... SEATTLE, Sept. 26 Today at the ... introduction of a,ground-breaking vaccine to eliminate epidemic ... conjugate vaccine, developed by the Meningitis,Vaccine Project, ... and,PATH and produced by Serum Institute of ...
... in Cancer is Published in the ... of the National Academy of Sciences, MOUNTAIN VIEW, ... focused on discovering, developing,and commercializing therapeutics that target the ... series of rigorous experiments to,elucidate CXCR7,s essential role in ...
... Oxford Finance Corporation,one of the nation,s leading providers ... announced it has finalized a $7 million secured ... will be used,to support Othera,s goal to become ... formulations for,ophthalmology, oncology and inflammatory disease. "This ...
Cached Biology Technology:PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 2ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 4ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 5Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals 2
(Date:9/15/2014)... Mass. (September 15, 2014) The so-called central ... makes proteinhas long provided a simplified explanation for ... living organisms. , In reality, of course, ... schema first articulated nearly 60 years ago by ... double-helix structure. For one, there are multiple types ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
(Date:9/15/2014)... that a single group of microorganisms may be responsible ... the oceans, with implications for the global carbon cycle ... essential molecule required by most life on this planet, ... of microorganisms because it is so large and complex. ... maintaining the brain and nervous systems, as well as ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3Researchers discover new producer of crucial vitamin 2
... also available in Spanish . , ... of Experimental Sciences of the University of ... this reason, immigrant teenagers have a lower probability of suffering ... eating habits. The study has not only analysed for the ...
... of UAB geneticists, doctors and biostatisticians has received $5.7 ... and test new treatments for neurofibromatosis, or NF. ... group called the NF Consortium. The coalition formed more ... clinical trials held across the nation looking at new ...
... the plot to blow up trans-Atlantic airlines with liquid explosives ... pressure on the airline industry, and Homeland Security, to find ... on airline passengers, but also to figure out what they ... Directorate (S&T) is teaming with scientists at the Los Alamos ...
Cached Biology News:Study reveals that immigrant teenagers eat better than Spanish teenagers 2UAB wins $5.7M neurofibromatosis grant 2UAB wins $5.7M neurofibromatosis grant 3Menace in a bottle 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is ... to identify recombinant plasmids. ... X-Gal and IPTG, ... appear blue, whereas recombinant ...
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
Biology Products: